Search research articles
Contact Us
Filters
Showing results (101-110 of 116) with videos related to
Page
of 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 14, 2020
Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial
Tim Eisen, Eleni Frangou, Bhavna Oza, et al.
Contemporary Clinical Trials
|
September 20, 2021
RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting
Angela Meade, Bhavna Oza, Eleni Frangou, et al.
Contemporary Clinical Trials
|
September 20, 2021
RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse
Bhavna Oza, Eleni Frangou, Ben Smith, et al.
Health Technology Assessment (Winchester, England)
|
May 26, 2016
The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer
John K Field, Stephen W Duffy, David R Baldwin, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2017
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study
Emeline Colomba, Gwénaël Le Teuff, Tim Eisen, et al.
Health Technology Assessment (Winchester, England)
|
September 9, 2024
Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT
Fiona Collinson, Kara-Louise Royle, Jayne Swain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 2, 2018
A Genetic Polymorphism in <i>CTLA-4</i> Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma
Xiaoyan Liu, Jesse J Swen, Meta H M Diekstra, et al.
Contemporary Clinical Trials Communications
|
November 18, 2024
Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and report
Angela Meade, Elena Frangou, Babak Choodari-Oskooei, et al.
British Journal of Cancer
|
June 23, 2022
A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)
Grant D Stewart, Sarah J Welsh, Stephan Ursprung, et al.
Cancers
|
June 24, 2022
Genome-Wide Meta-Analysis Identifies Variants in <i>DSCAM</i> and <i>PDLIM3</i> That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib
Meta H M Diekstra, Jesse J Swen, Loes F M van der Zanden, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 116) with videos related to
Sort By:
Page
of 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 14, 2020
Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial
Tim Eisen, Eleni Frangou, Bhavna Oza, et al.
Contemporary Clinical Trials
|
September 20, 2021
RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting
Angela Meade, Bhavna Oza, Eleni Frangou, et al.
Contemporary Clinical Trials
|
September 20, 2021
RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse
Bhavna Oza, Eleni Frangou, Ben Smith, et al.
Health Technology Assessment (Winchester, England)
|
May 26, 2016
The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer
John K Field, Stephen W Duffy, David R Baldwin, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2017
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study
Emeline Colomba, Gwénaël Le Teuff, Tim Eisen, et al.
Health Technology Assessment (Winchester, England)
|
September 9, 2024
Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT
Fiona Collinson, Kara-Louise Royle, Jayne Swain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 2, 2018
A Genetic Polymorphism in <i>CTLA-4</i> Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma
Xiaoyan Liu, Jesse J Swen, Meta H M Diekstra, et al.
Contemporary Clinical Trials Communications
|
November 18, 2024
Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and report
Angela Meade, Elena Frangou, Babak Choodari-Oskooei, et al.
British Journal of Cancer
|
June 23, 2022
A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)
Grant D Stewart, Sarah J Welsh, Stephan Ursprung, et al.
Cancers
|
June 24, 2022
Genome-Wide Meta-Analysis Identifies Variants in <i>DSCAM</i> and <i>PDLIM3</i> That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib
Meta H M Diekstra, Jesse J Swen, Loes F M van der Zanden, et al.
Page
of 12